Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 7/20 | 0.44 |
| ▸ | CCNH | P51946 | 7/20 | 0.44 |
| ▸ | MNAT1 | P51948 | 7/20 | 0.44 |
| ▸ | CDK2 | P24941 | 6/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | PAK4 | O96013 | 3/20 | 0.36 |
| ▸ | MELK | Q14680 | 1/20 | 0.33 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25947921 | 0.96 | CDK7 (0.45) | CDK7CCNHMNAT1CDK2CCNA2 | |
| SCHEMBL25948071 | 0.87 | CDK7 (0.45) | CDK7CCNHMNAT1CDK2CCNA2 | |
| SCHEMBL25952641 | 0.86 | CDK7 (0.59) | CDK7CCNHMNAT1CDK2CCNA2 | |
| SCHEMBL22924090 | 0.85 | CDK7 (0.45) | CDK7CCNHMNAT1CDK2CCNA2 | |
| SCHEMBL25947956 | 0.83 | CDK7 (0.36) | CDK7CCNHMNAT1 | |
| SCHEMBL22924043 | 0.83 | CDK7 (0.56) | CDK7CCNHMNAT1CDK2CCNA2 | |
| SCHEMBL25947836 | 0.80 | CDK7 (0.49) | CDK7CCNHMNAT1CDK2CCNA2 | |
| SCHEMBL22924079 | 0.79 | CDK7 (0.57) | CDK7CCNHMNAT1CDK2CCNA2 | |
| SCHEMBL25947875 | 0.79 | CDK7 (0.51) | CDK7CCNHMNAT1CDK2CCNA2 | |
| SCHEMBL25948158 | 0.78 | CDK7 (0.48) | CDK7CCNHMNAT1CDK2CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242534-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242534-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | CDK2, CDK5, CDK9 | CDK7 4/4885CCNH 40/4885MNAT1 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.